# Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma

> **NCT00075582** · PHASE3 · COMPLETED · sponsor: **Children's Oncology Group** · enrollment: 390 (actual)

## Conditions studied

- Adult Rhabdomyosarcoma
- Embryonal Childhood Rhabdomyosarcoma
- Embryonal-botryoid Childhood Rhabdomyosarcoma
- Previously Untreated Childhood Rhabdomyosarcoma

## Interventions

- **PROCEDURE:** conventional surgery
- **DRUG:** dactinomycin
- **DRUG:** cyclophosphamide
- **DRUG:** vincristine sulfate
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00075582
- **Lead sponsor:** Children's Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09-04
- **Primary completion:** 2012-08-13
- **Final completion:** 2021-09-30
- **Target enrollment:** 390 (ACTUAL)
- **Last updated:** 2021-11-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00075582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00075582, "Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00075582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*